Exact Sciences on Your Watchlist: Q4 Earnings Analysis Worth Monitoring

If you’re building an investment watchlist in the healthcare diagnostics space, Exact Sciences Corporation (EXAS) delivered results that warrant careful attention in the fourth quarter of 2025. The company reported earnings per share of negative 21 cents, matching analyst expectations exactly, while revenues surpassed projections—a mixed signal that health-conscious investors should evaluate closely.

Revenue Performance Signals Growth Momentum

The numbers tell an interesting story. Consolidated revenues reached $878.4 million in Q4 2025, representing a 23% increase year-over-year on a core basis. This figure exceeded the Zacks Consensus Estimate by 2.1%, demonstrating that top-line growth remains the company’s strength. For the full year, Exact Sciences generated $3.25 billion in revenues, up 18% on a core basis—a consistent growth trajectory worth noting for long-term watchlist candidates.

The market reacted with modest enthusiasm, as EXAS shares edged up just 0.07% following the announcement—suggesting investors are adopting a “prove it further” stance with this healthcare stock.

Dissecting the Business Segments: Where Growth Lives

Understanding where Exact Sciences generates revenue is crucial for watchlist evaluation. The Screening segment, powered by laboratory services including the company’s flagship Cologuard test and PreventionGenetics offerings, generated $695.1 million—a robust 26% year-over-year increase. This division represents the company’s bread-and-butter business in cancer detection.

Meanwhile, the Precision Oncology segment contributed $183.2 million, climbing 14% year-over-year. This division encompasses laboratory services from Oncotype products and therapy selection solutions, representing the higher-margin, specialized side of the business. The segment grew 12% on a core basis, slightly outpacing the broader market demand.

Profitability Picture: Margins Expanding, Expenses Surging

Here’s where the complexity emerges for watchlist investors. Exact Sciences’ gross profit climbed 25% year-over-year to $615.8 million, with gross margins expanding by 106 basis points to 70.1%—a positive indicator of operational efficiency and pricing power. For a healthcare diagnostics company, maintaining a 70%+ gross margin signals competitive advantage and strong market positioning.

However, the operating expense side presents concerns that sophisticated investors cannot ignore. Research and development expenses nearly doubled, rising 96% to $191.5 million. Sales and marketing expenses jumped 18% to $288.5 million, while general and administrative costs increased 14% to $218 million. Adjusted operating expenses reached $698 million, up 31% year-over-year, resulting in an adjusted operating loss of $82.2 million—more than double the prior-year loss of $40.8 million.

This divergence—expanding gross margins paired with accelerating operating losses—creates a watchlist consideration: Is the company investing for future growth, or are expenses outpacing revenue expansion?

Balance Sheet Stability: Cash Position Assessment

From a financial stability perspective, Exact Sciences ended Q4 2025 with $964.7 million in cash and marketable securities, compared to $1.04 billion a year prior. While this represents a modest decline, the company generated $491.4 million in cumulative operating cash flow during the year—more than double the prior year’s $210.5 million. This improving cash generation offers some comfort for investors concerned about the company’s runway and capital allocation flexibility.

The Abbott Merger Wild Card

A significant development for watchlist investors: Exact Sciences entered into a merger agreement with Abbott Laboratories in November 2025. The parties are progressing through regulatory review, targeting a Q2 2026 close. This acquisition introduces uncertainty but also potential upside if the deal closes successfully and Abbott’s distribution capabilities amplify Exact Sciences’ market reach. For watchlist purposes, this adds a binary outcome component worth monitoring through the regulatory process.

How Exact Sciences Stacks Against Healthcare Peers

For comparative context, several better-ranked healthcare stocks deserve watchlist consideration. Intuitive Surgical (ISRG), a leader in surgical robotics, holds a Zacks Rank #1 and reported Q4 2025 adjusted EPS of $2.53, surpassing estimates by 12.4%, with revenues of $2.87 billion beating expectations by 4.7%. The company boasts a 15.7% long-term earnings growth rate versus the industry’s 12.7%, and has beaten estimates in each of the last four quarters.

Cardinal Health (CAH), carrying a Zacks Rank #2, posted Q2 fiscal 2026 adjusted EPS of $2.63, exceeding consensus by 10%, with $65.6 billion in revenues topping projections by 0.9%. Cardinal Health demonstrates a 15% long-term growth rate, consistently outpacing the industry benchmark of 9.6%.

Align Technology (ALGN), another Rank #2 holding, reported Q4 2025 adjusted EPS of $3.29, beating estimates by 10.1%, with $1.05 billion in revenues outperforming forecasts by 5.3%. The company shows a 10.1% long-term growth rate comparable to industry expectations.

Investment Considerations: The Watchlist Verdict

For investors tracking Exact Sciences on their watchlist, the Q4 results present a nuanced picture. On the positive side, consistent revenue growth, margin expansion, and improving operating cash flow demonstrate the underlying business model’s resilience. The company’s Screening and Precision Oncology segments both delivered double-digit growth, validating market demand for its diagnostic solutions.

Conversely, the escalating operating losses, surge in research spending, and modest stock market response suggest investors remain skeptical about path to profitability. The pending Abbott merger introduces both opportunity and uncertainty—potentially unlocking distribution scale but also creating near-term execution risk.

For watchlist managers, Exact Sciences warrants continued monitoring rather than immediate action. The company currently carries a Zacks Rank #4 (Sell), and investors comparing it against higher-ranked healthcare peers might find more attractive entry points elsewhere in the sector. However, healthcare diagnostics remains a compelling long-term growth area, and strategic developments—particularly the Abbott deal closure and pipeline advancements like the Oncodetect molecular residual disease test showing positive breast cancer trial results—could alter this assessment.

The bottom line for your watchlist: Exact Sciences exhibits genuine growth metrics and market validation, but profitability timeline uncertainty and competitive positioning relative to better-ranked peers suggest a “hold for clarity” approach until regulatory approvals clarify the merger’s impact.